|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:CEO
|
gptkb:Michael_M._Morrissey
|
|
gptkbp:collaboratesWith
|
gptkb:Genentech
gptkb:Takeda_Pharmaceutical_Company
gptkb:Ipsen
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:FDAApproved
|
gptkb:Cabometyx
gptkb:Cometriq
|
|
gptkbp:focus
|
oncology
|
|
gptkbp:founded
|
1994
|
|
gptkbp:founder
|
gptkb:George_Yancopoulos
gptkb:Corey_Goodman
gptkb:Spyridon_Artavanis-Tsakonas
gptkb:Alexandra_Carolan
|
|
gptkbp:headquartersLocation
|
gptkb:Alameda,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Exelixis, Inc.
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:keyPerson
|
gptkb:Corey_Goodman
gptkb:Michael_M._Morrissey
|
|
gptkbp:marketCap
|
multi-billion USD (2023)
|
|
gptkbp:notable_drug
|
gptkb:Cabometyx
gptkb:Cometriq
|
|
gptkbp:numberOfEmployees
|
over 700
|
|
gptkbp:product
|
gptkb:Cabozantinib
gptkb:Cometriq
gptkb:Cotellic
Cabozyla
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:EXEL
|
|
gptkbp:therapeuticArea
|
gptkb:cancer
oncology
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:EXEL
|
|
gptkbp:website
|
https://www.exelixis.com/
|
|
gptkbp:bfsParent
|
gptkb:NASDAQ:EXEL
|
|
gptkbp:bfsLayer
|
7
|